Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,318.23 138.38 0.91%
S&P 500 1,651.81 12.77 0.78%
NASDAQ 3,482.18 30.05 0.87%
Ticker Volume Price Price Delta
STOXX 50 2,700.93 -1.76 -0.07%
FTSE 100 6,374.21 43.72 0.69%
DAX 8,229.51 13.78 0.17%
Ticker Volume Price Price Delta
NIKKEI 13,262.07 254.79 1.96%
TOPIX 1,106.37 19.97 1.84%
HANG SENG 21,099.11 -126.77 -0.60%

Dynavax to Present at the Cowen and Company 33rd Annual Healthcare Conference


Dynavax to Present at the Cowen and Company 33rd Annual Healthcare Conference

BERKELEY, CA -- (Marketwire) -- 02/26/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the Cowen and Company 33rd Annual Healthcare Conference in Boston on Tuesday, March 5, 2013 at 8:40 a.m. Eastern Time (5:40 a.m. Pacific Time).

Dino Dina, M.D., Chief Executive Officer of Dynavax, will provide a company overview. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at http://investors.dynavax.com/newsevents.cfm.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Dynavax's lead product candidate is HEPLISAV (TM), a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.

Contact: Michael Ostrach Vice President and Chief Business Officer 510-665-7257 mostrach@dynavax.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement